{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:09:04Z","timestamp":1791216544207,"version":"4.1.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>High-dose methotrexate (HDMTX) is the cornerstone of the treatment for primary central nervous system lymphoma (PCNSL). The prevention of drug-induced toxicities is critical. This study aims to identify key factors associated with HDMTX-induced toxicities (hematotoxicity, hepatotoxicity and nephrotoxicit) in 713 Chinese PCNSL patients undergoing 3021 HDMTX treatment courses. Demographic data, administration information, laboratory tests, area under the curve, co-medications, and 30 single nucleotide polymorphisms were collected to analyze the association of HDMTX-related toxicities using PLINK and SPSS. Higher ALB level, female, ABCB1 rs1045642, MTHFR rs1801131, and MTHFD1 rs2236225 were associated with lower risk of anemia, while the combination of furosemide, torasemide, bumetanide, and levetiracetam associating with higher risk. Co-use of torasemide had higher incidence of neutropenia. Higher level of ALB was correlated with less leukopenia; torasemide and rs2236225 were related to more leukopenia. Female, furosemide, rs1801133, ABCG2 rs2231142, ABCC2 rs717620 were related to more thrombocytopenia, while rs1045642 and high ALB were related to less. Rs1801131 and female were correlated with more hepatotoxicity, whereas furosemide was correlated with less. In nephrotoxicity, female and rs1801394 were correlated with less, MTHFR rs1801131 and rs1801133 were correlated with more. In conclusion, higher ALB levels had a lower risk of HDMTX toxicities; loop diuretics and levetiracetam generally accelerated the occurrence of toxicities. Rs1801133\u00a0GG, rs1128503\u00a0GG + AG, rs2231142 AA+ AC, rs717620\u00a0TT + GT were associated with increased risk of toxicity; rs1045642\u00a0TT and rs1801394\u00a0GG + AG were less likely to develop toxicity.<\/jats:p>","DOI":"10.3389\/fphar.2025.1561818","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T05:27:04Z","timestamp":1754285224000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk factors associated with high-dose methotrexate induced toxicities in primary central nervous system lymphoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenshu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifeng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/hon.2759","article-title":"Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies","volume":"38","author":"Amitai","year":"2020","journal-title":"Hematol. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.31557\/APJCP.2022.23.11.3859","article-title":"Association analysis of GSTP1-rs1695 polymorphism with the risk of oral cancer: a literature review, an updated Meta- analysis, and a structural assessment","volume":"23","author":"Baghaei","year":"2022","journal-title":"Asian Pac J. Cancer Prev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/PGPM.S170557","article-title":"Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study","volume":"11","author":"Baghdadi","year":"2018","journal-title":"Pharmgenomics Pers. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1177\/1060028013511951","article-title":"Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination","volume":"48","author":"Bain","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.3390\/ijms20205023","article-title":"Methotrexate an old drug with new tricks","volume":"20","author":"Bedoui","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1600-0773.1991.tb01286.x","article-title":"Acute hepatotoxicity after high-dose methotrexate administration to rats","volume":"69","author":"Bremnes","year":"1991","journal-title":"Pharmacol. Toxicol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1066062","DOI":"10.1080\/2162402X.2015.1066062","article-title":"Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies","volume":"5","author":"Cook","year":"2016","journal-title":"Oncoimmunology"},{"key":"B8","article-title":"Common terminology criteria for adverse events (CTCAE) version 5.0","year":"2024"},{"key":"B9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/phar.2516","article-title":"Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma","volume":"41","author":"DeFino","year":"2021","journal-title":"Pharmacotherapy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.3899\/jrheum.111593","article-title":"ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis","volume":"39","author":"de Rotte","year":"2012","journal-title":"J. Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s11033-021-06724-z","article-title":"Influence of GSTP1 rs1695 polymorphism on survival in Male patients' amyotrophic lateral sclerosis: a genetic association study in Brazilian population","volume":"49","author":"de Sousa Barros","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2450\/2020.0062-20","article-title":"GSTP1 rs1695 and rs1871042, and SOD2 rs4880 as molecular markers of lipid peroxidation in blood storage","volume":"19","author":"do Nascimento","year":"2021","journal-title":"Blood Transfus."},{"key":"B13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-4939-6442-0_5","article-title":"The MassARRAY\u00ae system for targeted SNP genotyping","volume":"1492","author":"Ellis","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3109\/10428194.2011.639880","article-title":"Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia","volume":"53","author":"Erculj","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"B15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2478\/raon-2013-0076","article-title":"The influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in children with Non-Hodgkin malignant lymphoma","volume":"48","author":"Erculj","year":"2014","journal-title":"Radiol. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"800","DOI":"10.22038\/ijbms.2020.41754.9858","article-title":"Polymorphisms within methotrexate pathway genes: relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia","volume":"23","author":"Esmaili","year":"2020","journal-title":"Iran. J. Basic Med. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/sj.bjc.6601472","article-title":"Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas","volume":"90","author":"Ferreri","year":"2004","journal-title":"Br. J. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/cpdd.279","article-title":"Methotrexate polyglutamate monitoring in patients with crohn's disease","volume":"6","author":"Fischer","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/bjh.19238","article-title":"Primary central nervous system marginal zone lymphoma","volume":"204","author":"Flospergher","year":"2024","journal-title":"Br. J. Haematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s002800000111","article-title":"Maximum tolerated doses of methotrexate and 7-hydroxy-methotrexate in a model of acute toxicity in rats","volume":"46","author":"Fuskevag","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41397-018-0047-z","article-title":"Genetic markers in methotrexate treatments","volume":"18","author":"Giletti","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e24423","DOI":"10.1097\/MD.0000000000024423","article-title":"Evaluating the role of GSTP1 genetic polymorphism (Rs1695, 313A>G) as a predictor in cyclophosphamide-induced toxicities","volume":"100","author":"Gong","year":"","journal-title":"Med. Baltim."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1111\/jcpt.13505","article-title":"Association of MTHFR and ABCB1 polymorphisms with MTX-Induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study","volume":"46","author":"Gong","year":"","journal-title":"J. Clin. Pharm. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/17425255.2020.1732348","article-title":"Transcription factor-mediated regulation of the BCRP\/ABCG2 efflux transporter: a review across tissues and species","volume":"16","author":"Gorczyca","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/tpj.2014.81","article-title":"Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia","volume":"15","author":"Gregers","year":"2015","journal-title":"Pharmacogenomics J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/medicina57101050","article-title":"Polymorphism in gene for ABCC2 transporter predicts methotrexate drug survival in patients with psoriasis","volume":"57","author":"Grzelj","year":"","journal-title":"Med. Kaunas."},{"key":"B27","doi-asserted-by":"publisher","first-page":"111456","DOI":"10.1016\/j.biopha.2021.111456","article-title":"Polymorphisms in GNMT and DNMT3b are associated with methotrexate treatment outcome in plaque psoriasis","volume":"138","author":"Grzelj","year":"","journal-title":"Biomed. Pharmacother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e29518","DOI":"10.7759\/cureus.29518","article-title":"Overview of methotrexate toxicity: a comprehensive literature review","volume":"14","author":"Hamed","year":"2022","journal-title":"Cureus"},{"key":"B29","doi-asserted-by":"publisher","first-page":"759805","DOI":"10.3389\/fonc.2021.759805","article-title":"Effect of polymorphisms of ABCB1 and MTHFR on methotrexate-related toxicities in adults with hematological malignancies","volume":"11","author":"Han","year":"2021","journal-title":"Front. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/leu.2008.66","article-title":"Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia","volume":"22","author":"Huang","year":"2008","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2125.2011.04084.x","article-title":"Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate","volume":"73","author":"Joerger","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.bjc.6605559","article-title":"Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial","volume":"102","author":"Joerger","year":"2010","journal-title":"Br. J. Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e29738","DOI":"10.1002\/pbc.29738","article-title":"Hypoalbuminemia and not undernutrition predicts high-dose methotrexate-induced nephrotoxicity in children with acute lymphoblastic leukemia in resource-constrained centers","volume":"69","author":"Khera","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.clinthera.2012.06.022","article-title":"ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis","volume":"34","author":"Kim","year":"2012","journal-title":"Clin. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1182\/blood-2006-10-054528","article-title":"Ancestry and pharmacogenetics of antileukemic drug toxicity","volume":"109","author":"Kishi","year":"2007","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.3390\/ijms21103483","article-title":"Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers","volume":"21","author":"Ko\u017ami\u0144ski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00280-022-04498-0","article-title":"Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia","volume":"91","author":"Li","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/17425255.2024.2332366","article-title":"Risk factors associated with high-dose methotrexate induced toxicities","volume":"20","author":"Li","year":"2024","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.2147\/CMAR.S207959","article-title":"Identifying risk factors for high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia","volume":"11","author":"Li","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00228-023-03491-7","article-title":"Risk factors for acute kidney injury after high-dose methotrexate therapy: a single-center study and narrative review","volume":"79","author":"Liang","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e82681","DOI":"10.1371\/journal.pone.0082681","article-title":"Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"key":"B43","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/jcph.1544","article-title":"Effect of levetiracetam on time to high-dose methotrexate clearance in patients with hematologic malignancies","volume":"60","author":"Lou","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1007\/s11033-020-05481-9","article-title":"Molecular mechanism of action and pharmacokinetic properties of methotrexate","volume":"47","author":"Maksimovic","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.xphs.2018.01.004","article-title":"Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma","volume":"107","author":"Mei","year":"","journal-title":"J. Pharm. Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jpba.2018.06.011","article-title":"Simultaneous determination of plasma methotrexate and 7-hydroxy methotrexate by UHPLC-MS\/MS in patients receiving high-dose methotrexate therapy","volume":"158","author":"Mei","year":"","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B47","year":"2024"},{"key":"B48","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1146\/annurev-pharmtox-010617-052713","article-title":"The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease","volume":"58","author":"Nigam","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1152\/physrev.00025.2013","article-title":"The organic anion transporter (OAT) family: a systems biology perspective","volume":"95","author":"Nigam","year":"2015","journal-title":"Physiol. Rev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/pbc.24371","article-title":"Drug-drug interaction between methotrexate and levetiracetam in a child treated for acute lymphoblastic leukemia","volume":"60","author":"Parentelli","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/08880018.2019.1705949","article-title":"Association of ABCC2 with levels and toxicity of methotrexate in Malaysian childhood acute lymphoblastic leukemia (ALL)","volume":"37","author":"Razali","year":"2020","journal-title":"Pediatr. Hematol. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1177\/1060028016661572","article-title":"Methotrexate elimination when coadministered with levetiracetam","volume":"50","author":"Reeves","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00277-016-2795-7","article-title":"Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia","volume":"95","author":"Reiss","year":"2016","journal-title":"Ann. Hematol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"757464","DOI":"10.3389\/fphar.2021.757464","article-title":"The role of genetic polymorphisms in high-dose methotrexate toxicity and response in hematological malignancies: a systematic review and meta-analysis","volume":"12","author":"Song","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2019.07.003","article-title":"The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: a systematic review","volume":"142","author":"Van der Beek","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1158\/1078-0432.CCR-08-2940","article-title":"Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo","volume":"15","author":"Vlaming","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/j.ejca.2011.03.032","article-title":"Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia","volume":"47","author":"Wang","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"12354","DOI":"10.1002\/cam4.5936","article-title":"Effect of co-medications and potential risk factors of high-dose methotrexate-mediated acute hepatotoxicity in patients with osteosarcoma","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1578033","DOI":"10.3389\/fphar.2025.1578033","article-title":"Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma","volume":"16","author":"Wei","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/cncr.26472","article-title":"Germline genetic polymorphisms May influence chemotherapy response and disease outcome in osteosarcoma: a pilot study","volume":"118","author":"Windsor","year":"2012","journal-title":"Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1003812","DOI":"10.3389\/fphar.2022.1003812","article-title":"Association between high-dose methotrexate-induced toxicity and polymorphisms within methotrexate pathway genes in acute lymphoblastic leukemia","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"402","DOI":"10.5414\/CP203423","article-title":"Population pharmacokinetic study of delayed methotrexate excretion in children with acute lymphoblastic leukemia","volume":"57","author":"Zang","year":"2019","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1515\/dmpt-2015-0011","article-title":"Association of ABCB1, ABCC5 and xanthine oxidase genetic polymorphisms with methotrexate adverse reactions in Mexican pediatric patients with ALL","volume":"30","author":"Zaruma-Torres","year":"2015","journal-title":"Drug Metab. Pers. Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2147\/PGPM.S404949","article-title":"MTHFR and MTRR genetic polymorphism of methotrexate therapy outcomes in early rheumatoid arthritis","volume":"16","author":"Zhang","year":"2023","journal-title":"Pharmgenomics Pers. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1561818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T05:27:06Z","timestamp":1754285226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1561818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":64,"alternative-id":["10.3389\/fphar.2025.1561818"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1561818","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"article-number":"1561818"}}